Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H7NO.C4H6O6 |
Molecular Weight | 259.2127 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=CN=CC=C1.O[C@H]([C@@H](O)C(O)=O)C(O)=O
InChI
InChIKey=NPORIZAYKBQYLF-LREBCSMRSA-N
InChI=1S/C6H7NO.C4H6O6/c8-5-6-2-1-3-7-4-6;5-1(3(7)8)2(6)4(9)10/h1-4,8H,5H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
Nicotinyl alcohol is a direct-acting vasolidator, that may decrease the blood pressure and it is a cholesterol-lowering agent. Nicotinyl alcohol as a tartrate salt led to the efficiency improvements in patients with intermittent claudication. In addition, nicotinyl alcohol alone or associated with other drugs was studied in the treatment of radicular syndromes; and was shown, that the effect had not been due to mechanical compression.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Other AEs: Increased appetite, Skin rash... Other AEs: Increased appetite (15%) Sources: Skin rash (36%) Itching (37%) Flushing (68%) Nausea (50%) Abdominal pain (15%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Increased appetite | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Skin rash | 36% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Itching | 37% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Nausea | 50% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Flushing | 68% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Metabolism of myosmine in Wistar rats. | 2005 Nov |
|
Reaction of the tobacco alkaloid myosmine with hydrogen peroxide. | 2006 Jan |
|
catena-Poly[[bis-[2-(2,3-dimethyl-anilino)benzoato-κO]cadmium(II)]-di-μ-3-pyridylmethanol-κN:O;κO:N]. | 2008 Feb 6 |
|
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. | 2008 Mar 15 |
|
Oxidation of alcohols using a manganese (II) complex based on a pentakis benzimidazole amide ligand. | 2009 Oct 1 |
|
Synthesis and Structural Characterization of a Metal Cluster and a Coordination Polymer Based on the [Mn(6)(mu(4)-O)(2)] Unit. | 2010 |
|
The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. | 2010 Jan |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13383231
25 mg tablet 4 times a daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
235354
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
147492
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
m7882
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
5G605ZIE90
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
SUB14652MIG
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
228-199-1
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
DTXSID90977232
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
C77152
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
100000079995
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
93578
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
6164-87-0
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL1235535
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD